<DOC>
	<DOC>NCT01831466</DOC>
	<brief_summary>The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.</brief_summary>
	<brief_title>Tofacitinib Ointment For Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails) If received certain treatments, should be off treatment for a minimum period of time (washout) Currently have nonplaque forms of psoriasis or druginduced psoriasis Require treatment with or cannot stop medication(s) prohibited during the study Have certain laboratory abnormalities at Baseline Current or history of certain infections Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>vulgaris</keyword>
	<keyword>topical treatment</keyword>
	<keyword>skin diseases</keyword>
	<keyword>papulosquamous</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>CP-690550</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>psoriasis</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
	<keyword>itch</keyword>
	<keyword>nail psoriasis</keyword>
</DOC>